Hemotrial Un proyecto de SEHH

Ensayo clínico

Estudio aleatorizado, doble ciego, de grupos paralelos de fase III de la eficacia y la seguridad de dabigatrán etexilato (150 mg bid) oral en comparación con warfarina (INR 2,0-3,0) para un tratamiento durante 6 meses de la tromboembolia venosa sintomática aguda después del tratamiento inicial durante al menos 5 días con un anticoagulante parenteral aprobado para esta indicación. RE-COVER IIA phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II

  • Guardar

  • Imprimir
  • << Volver

Resumen

2017-03-15 04:05:22
2007-002631-86
1160.46
Estudio aleatorizado, doble ciego, de grupos paralelos de fase III de la eficacia y la seguridad de dabigatrán etexilato (150 mg bid) oral en comparación con warfarina (INR 2,0-3,0) para un tratamiento durante 6 meses de la tromboembolia venosa sintomática aguda después del tratamiento inicial durante al menos 5 días con un anticoagulante parenteral aprobado para esta indicación. RE-COVER IIA phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II
RE-COVER II
1160.46

PROMOTORES DEL ENSAYO
Nombre del promotor Organización Persona de contacto País
Boehringer Ingelheim España, S.A. Spain

Fármacos

  INFORMACIÓN DE FÁRMACOS USADOS:
  FÁRMACO 1:
Test Warfarin tablets BP 1 mg
IVAX Pharmaceutical dabigatran etexilate
BIBR 1048 Capsule, hard
Oral use

Detalles del Fármaco (Principio Activo):

BIBR 1048

Concentración del fármaco:

mg milligram(s) equal

150

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

No
  FÁRMACO 2:
Comparator Warfarin tablets BP 3 mg
IVAX Pharmaceuticals Warfarin tablets BP 1 mg
Tablet
Oral use

Detalles del Fármaco (Principio Activo):

Concentración del fármaco:

mg milligram(s) equal

1

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

No
  FÁRMACO 3:
Comparator Warfarin tablets BP 5 mg
IVAX Pharmaceuticals Warfarin tablets BP 3 mg
Tablet
Oral use

Detalles del Fármaco (Principio Activo):

Concentración del fármaco:

mg milligram(s) equal

3

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

No
  FÁRMACO 4:
Comparator
Warfarin tablets BP 5 mg
Tablet
Oral use

Detalles del Fármaco (Principio Activo):

Concentración del fármaco:

mg milligram(s) equal

5

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

No
  INFORMACIÓN DE PLACEBOS USADOS:
  PLACEBO 1:

Si
Capsule, hard

Oral use
  PLACEBO 2:

Si
Tablet

Oral use
  PLACEBO 3:

Si
Tablet

Oral use
  PLACEBO 4:

Si
Tablet

Oral use

Información General



Enfermedad Trombótica

tromboembolia venosa sintomática agudaLa tromboembolia venosa se define como la incidencia compuesta de trombosis venosa profunda de la pierna (incluyendo la vena cava inferior) y embolia pulmonarAcute symptomatic VTEVTE is defined as the composite incide


The primary objective is to investigate the efficacy of dabigatran etexilate 150 mg bid administered orally compared to warfarin PRN to maintain an INR of 2.0-3.0 for a 6 month treatment period according to the study endpoints in patients with acute symptomatic Venous Thromboembolic Event (VTE is defined as the composite incidence of Deep Vein Thrombosis of the leg and pulmonary embolism.)

The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.

No


1. Acute symptomatic uni- or bilateral DVT of the leg involving proximal veins, and/orPE confirmed by definitive objective clinical test in patients for whom at least 6 months of anticoagulant therapy is considered appropriate by the investigator2. Male or female, being 18 years of age or older3. Written informed consent for study participation

1. Overt symptoms of VTE for longer than 2 weeks prior to enrolment2. PE satisfying at least one of the following criteria:- Haemodynamic instability- Embolectomy is indicated or performed- Thrombolytic therapy is indicated or performed- Suspected source of PE is other than the legs3. Actual or anticipated use of vena cava filter4. Contraindications to anticoagulant therapy including contraindications to heparins or other alternate approved therapy used for initial treatment, and warfarin5. Patients who in the investigator?s opinion should not be treated with warfarin6. Allergy to heparins (including history of heparin induced thrombocytopenia) or other alternate approved therapy used for initial treatment, warfarin or dabigatran, or to one of the excipients included in these medications7. In case of anticipated study related diagnostic procedures requiring contrast medium:- Elevated serum creatinine, which in the investigator?s opinion contraindicatesthese examinations- Known allergy to radio opaque contrast media or iodine, which in theinvestigator?s opinion contraindicates these examinations8. Patients who in the investigator?s judgement are perceived as having an excessive risk of bleeding (examples listed in the protocol)9. Known anaemia (haemoglobin < 100 g·L-1)10. Need of anticoagulant treatment for disorders other than VTE11. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrolment (investigator?s judgement), acute bacterial endocarditis or history of myocardial infarction within the last 3 months12. Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3xULN based on the local lab results obtained at screening and prior to randomisation13. Liver disease expected to have any potential impact on survival (e.g. acute hepatitis, possibly active hepatitis B, hepatitis C or cirrhosis, but not Gilbert?s syndrome or hepatitis A with complete recovery)14. Severe renal impairment (estimated creatinine clearance equal or less than 30 ml/min)15. Women who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study16. Patients considered unsuitable for inclusion by the investigator, e.g. becauseconsidered unreliable to comply with the requirements for follow-up during the studyand/or compliance with study drug administration, has a life expectancy less than theexpected duration of the trial due to concomitant disease, or has any condition whichin the opinion of the investigator would not allow safe participation in the study (e.g.,drug addiction, alcohol abuse)17. Participation in another clinical trial with an investigational drug during the last 30days or previous participation in this study or RE-COVER I (1160.53)

A composite of recurrent symptomatic VTE and deaths related to VTE within 6 months. VTE is defined as the composite incidence of DVT of the leg (including the inferior caval vein) and PE.All recurrent VTE require objective verification by definitive diagnostic evaluation:- Any suspected DVT must be confirmed by venous compression ultrasonography (CUS) or venography.- Any suspected PE must be confirmed by one of the following: ventilation-perfusion(V-Q) lung scan, pulmonary angiography, or spiral (helical) CT.In case of death, autopsy is an additional way to confirm VTE.

Fase III
  DISEÑO DEL ENSAYO:

Si
Si

No
No

Si
Si

No
No
  COMPARADOR DEL ENSAYO CONTROLADO:

Si
No

No
No

Si

Centros participantes:


Si
Information no disponible en EudraCT
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO:

2
6
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO EN ESPAÑA:


  POBLACIÓN DE PACIENTES EN EL ESTUDIO:
  Población de pacientes: 1

Rango de edad:


0
1

1

Sexo:


1
1

Número planeado de pacientes a incluir:


64

Para estudios internacionales:


750
2550

Investigadores

  INVESTIGADORES QUE PARTICIPAN EN EL ESTUDIO

Estado actual


Por Determinar



En Marcha